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ABSTRACT
Pancreatic carcinoma ranks among the most lethal of human cancers. Besides 
late detection, other factors contribute to its lethality, including a high degree of 
chemoresistance, invasion, and distant metastases. Currently, the mainstay of therapy 
involves resection of local disease in a minority of patients (Whipple procedure) and 
systemic gemcitabine. While systemic chemotherapy has some benefit, even with 
optimal treatment, the five year survival after diagnosis is dismal. Thus, treatment of 
pancreatic carcinoma remains a tremendous unmet need.
The organometallic compound tris DBA palladium is a potent inhibitor of 
N-myristoyltransferase 1 (NMT1), an enzyme that catalyzes the transfer of myristate 
to protein substrates. This compound is highly effective in vivo against murine models 
of melanoma with both mutant and wild type b-RAF genotypes. Based upon the 
signaling similarities between melanoma and pancreatic carcinoma, we evaluated 
the efficacy of tris DBA palladium in vitro and in vivo against pancreatic carcinoma. 
We found that tris DBA palladium decreased proliferation and colony formation of 
pancreatic cancer cells in vitro. In an orthotopic mouse model, tris DBA palladium was 
highly active in inhibiting growth, ascites production, and distant metastases in vivo. 
Furthermore, tris DBA palladium impaired chemotaxis and inhibited cilia formation in 
Pan02 cells in a NMT1-dependent manner. We propose that NMT1 is a novel regulator 
of cilia formation and tris DBA palladium a novel inhibitor of cilia formation and 
metastasis in pancreatic cancer. Thus, further evaluation of tris DBA palladium for 
the treatment of pancreatic cancer is warranted.
INTRODUCTION
Carcinoma of the exocrine pancreas remains among 
one of the deadliest solid tumors in humans. Factors that 
contribute to the high degree of mortality are late detection, 
when distant metastases are present, anatomical location 
making definitive surgery difficult, and advanced age. Over 
90% of pancreatic adenocarcinomas exhibit mutations in 
Kras, which is currently undruggable [1, 2]. Thus, surgery 
and radiation alone are insufficient to control the disease. 
               Research Paper
Oncotarget51570www.impactjournals.com/oncotarget
Chemotherapy is commonly used, with gemcitabine and 
folfirinox being the mainstays of therapy [3].
Additional studies have attempted to increase the 
success of therapy of pancreatic adenocarcinoma. The use 
of hedgehog inhibitors to block signaling and desmoplasia 
resulted in decreased desmoplasia, but with no clinical 
benefit [4]. Thus, novel therapies are urgently needed for 
this common and lethal cancer [5].
Tris DBA palladium (Tris DBA thereinafter) is a 
small molecule that we found to be a novel inhibitor of 
N-myristoyltransferase 1 (NMT1) [6]. NMT1 is responsible 
for myristoylation of multiple proteins, including the src 
family kinase (SFK) proteins [7, 8]. Lack of myristoylation 
compromises the function of target proteins, as it prevents 
their localization to cell membranes [9]. In this study, we 
tested the possibility that tris DBA could have anti-tumor 
effects in pancreatic adenocarcinoma. Here we demonstrate 
that tris DBA exhibits a potent antiproliferative effect on 
pancreatic cancer cell lines in vitro. Furthermore, in an 
orthotopic pancreatic xenograft mouse model, tris DBA 
decreased primary tumor growth and the occurrence 
of distant metastasis. To understand the mechanism by 
which tris DBA reduced tumor metastasis, we examined 
the effect of this compound on cancer cell migration and 
cilia formation. Cilia mediate directed cell migration and 
their presence in human pancreatic carcinoma has been 
recently associated with poor prognosis [10]. We propose 
that tris DBA should be studied further as a potential novel 
treatment for pancreatic carcinoma with non-overlapping 
mechanisms of action to other drugs.
RESULTS
Tris DBA is highly active in vivo against melanoma 
driven by different genetic alterations [6]. Given that 
melanoma and pancreatic carcinoma share some common 
genetic and signaling features, including loss of p16Ink4a, 
predisposing to melanoma and pancreatic carcinoma, we 
evaluated the effect of tris DBA treatment in pancreatic 
carcinoma.
Tris DBA decreased pancreatic cancer cell 
growth in vitro
We tested the effect of tris DBA in the murine 
pancreatic carcinoma cell line Pan02 and found that it 
was highly effective in reducing proliferation after 24 h 
of treatment in a dose-dependent fashion (Figure 1A). 
To analyze the effect of longer treatments, we performed 
colony forming assays using different concentrations of 
the compound. Tris DBA significantly reduced colony 
formation in Pan02 cells (Figure 1B, 1C), suggesting 
impaired proliferation and/or survival of cells upon 
treatment. Tris DBA was also highly effective in reducing 
colony formation in the human pancreatic cell line 
PANC1 at 0.5 µM (Figure 1D, 1E). In Pan02 cells, tris 
DBA treatment decreased the phosphorylation of Akt 
and p42/44 MAPK at approximately 10 µM, whereas 
phosphorylation of S6 kinase and FoxM1 were unaffected 
(Supplementary Figure 1). A significant inhibitory effect 
of the compound in cell growth occurred at a much lower 
compound concentration (1 µM) than the one needed to 
inhibit signaling through Akt and p42/44 MAPK (10 µM). 
Therefore, it is unlikely that the effect of tris DBA in 
proliferation and colony formation can be explained by 
alterations in the MAPK or Akt signaling pathways.
Tris DBA decreased pancreatic tumor growth 
and metastasis in an orthotopic mouse model
To determine whether tris DBA demonstrates 
efficacy against pancreatic carcinoma in vivo, Pan02 cells 
were orthotopically transplanted into mice. The mice 
were then randomized to vehicle control or tris DBA. 
Tris DBA treatment led to significant decreases in tumor 
weight (Figure 2A) and a reduction in metastatic events 
(Figure 2B) compared to control-treated animals. No 
histological differences were observed between the control 
and treated groups (Supplementary Figure 2).
Tris DBA impaired chemotactic cell migration in 
pancreatic cancer cells in vitro
The striking metastasis inhibitory effect of tris DBA 
in vivo prompted us to analyze whether this drug directly 
targeted metastasis or whether its effect on metastasis 
was an indirect consequence of decreased primary tumor 
volume. Since the migratory ability of cancer cells is 
associated with its metastatic capacity we investigated the 
effects of tris DBA in pancreatic cancer cell migration. 
Chemokinesis (cell migration that is independent of a 
gradient of soluble factors) and chemotaxis (cell migration 
induced by a gradient of soluble factors), were modeled 
in vitro using trans-well migration assays. For 
chemokinesis, cells were plated in the upper chamber in 
medium containing 10% FBS whereas for chemotaxis 
assays, cells were plated in the upper chamber in medium 
containing 1% FBS. In all cases, the lower chambers were 
filled with medium containing 10% FBS. Interestingly, 
treatment with tris DBA significantly decreased the ability 
of Pan02 cells to migrate in the presence (Figure 3A), 
but not in the absence (Figure 3B), of a FBS gradient. 
This suggested that chemotaxis but not chemokinesis, 
was impaired by drug treatment. To verify that impaired 
attachment or decreased survival of treated Pan02 cells 
in 1% versus 10% FBS was not accounting for the 
differences in trans-well migration, we performed a 
parallel assay in regular growth plates. Control or tris 
DBA-treated Pan02 cells were plated in the presence of 
1% or 10% FBS for 6 h. Cell number was quantified by 
colorimetry after crystal violet staining and no differences 
were found across treatments (Supplementary Figure 3). 
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Figure 1: Tris DBA decreases proliferation and colony forming ability of pancreatic carcinoma cells. (A) Pan02 cells 
were treated for 24 h with the indicated concentrations of tris DBA or control vehicle (DMSO). Cells were counted 24 h after treatment 
and average of quadruplicate experiments ± S.D. represented. (*) p < 0.05; (**) p < 0.005 (***) p < 0.0005 (Student’s t test) (B) Pan02 
were plated at low density and treated 24 h after seeding with the indicated concentrations of tris DBA or vehicle control. Number of 
colonies visualized with crystal violet 6 days after treatment was quantified and represented as average ± S.D. of triplicate experiments. 
(*) p < 0.001; (**) p < 0.00001 (Student’s t test). (C) Representative images of crystal violet-stained colonies after treatment of Pan02 
cells with the indicated concentrations of tris DBA. (D) PANC1 were plated at low density and treated 24 h after seeding with the indicated 
concentrations of tris DBA or vehicle control. Number of colonies visualized with crystal violet 6 days after treatment was quantified and 
represented as average ± S.D. of triplicate experiments. (*) p < 0.001; (**) p < 0.0001 (Student’s t test). (E) Representative images of crystal 
violet-stained colonies after treatment of PANC1 cells with the indicated concentrations of tris DBA.
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Figure 2: Tris DBA is as efficacious against primary tumor growth and metastasis. 6-8 week old 
C57bl/6 mice, in a group of five for vehicle control and a group of seven for tris DBA, were injected orthotopically 
with 5 × 105 Pan02 cells. One week post injection, they receive vehicle (coconut oil), tris-DBA 6.4 mg/kg, 
all three times weekly. (A) At sacrifice, tumors were removed and their weight measured. Data shown are mean +/− SEM from a single 
experiment. *p < 0.05, One way ANOVA with Tukey’s MCT. (B) Gross liver metastatic events were counted at sacrifice, results were not 
significant (p = 0.34).
Figure 3: Tris-DBA impairs chemotaxis but not chemokinesis in Pan02 cells. Pan02 were assayed for chemotaxis and 
chemokinesis in the presence or absence of tris-DBA (1mM) using in vitro trans-well assays. For chemotaxis (A) cells were plated in 
medium containing 1% FBS in the presence or absence of compound. Lower chambers were filled with medium containing 10% FBS. 
Cell migration was assessed after 6 hours by counting crystal violet-stained cells under the microscope. Graph represents average number 
of migrated cells normalized to non-treated control, from three independent experiments. Bars, S.D. (*) p = 0.9 × 10−5 (Student’s t-test). 
For chemokinesis (B), the assay was performed under the same conditions with the exception that cells were plated in medium containing 
10% FBS. Representative pictures of filters stained with crystal violet are shown at the right of each graph. For clarity, color images were 
inverted using Adobe Photoshop. Bar, 20 µm.
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This indicated that the presence of a serum gradient, 
rather than the final concentration of serum in the plating 
medium, impacted the migratory ability of Pan02 cells 
in the presence of tris DBA. We concluded that in vitro 
chemotaxis but not chemokinesis of Pan02 cells was 
affected by tris DBA treatment. 
Additionally, we did not observe differences in the 
number or size of focal adhesions (as analyzed by FAK 
staining) after compound treatment (Supplementary 
Figure 3). This also suggests that the intrinsic ability of 
cells to migrate may not be affected by the compound. 
We conclude that tris DBA impaired the ability of cells 
to sense a gradient of soluble factors, which is a known 
trigger of cell migration. 
Tris DBA reduces cilia formation in both Pan02 
and PANC1 cells
Because cilia have been associated with cellular 
sensing of gradients of diffusible signals [11, 12], we tested 
whether tris DBA affected cilia formation in Pan02 cells. 
To identify cilia, we used an antibody against the well-
characterized cilia marker acetylated tubulin. Interestingly, 
treatment of Pan02 cells with tris DBA caused a 
significant decrease in the percent of cells forming cilia 
(Figure 4A, 4C). The effect of tris DBA in cilia formation 
was not cell-type dependent, as the compound also 
decreased cilia formation in the human pancreatic cancer 
cell line PANC1 (Figure 4B, 4D). 
Taken together, our data suggest that tris DBA 
impaired chemotaxis of Pan02 cells by decreasing cilia 
formation and affecting the ability of cells to sense a 
gradient of chemotactic factors. The inhibitory effect of 
tris DBA on chemotaxis and cilia formation suggests a 
specific effect of this compound in metastasis in vivo. 
To investigate whether treatment with tris DBA 
affected cilia formation in vivo, we analyzed cilia 
formation in primary tumors from mice treated with 
vehicle control or tris-DBA. We stained tumor sections 
for the cilia marker acetylated tubulin and quantified cilia 
formation (Figure 5A). The detection of mitotic spindles 
was used as a positive control for antibody performance 
(Figure 5B). Interestingly, we observed a significant 
decrease in the presence of cilia in tumors from tris DBA 
treated mice (Figure 5A, 5B), suggesting that tris DBA 
decreases pancreatic tumor cilia formation in vivo. 
To better understand the molecular mechanism 
mediating the effect of tris DBA on cilia formation, 
we analyzed whether NMT1, the main target of this 
compound, affected cilia formation in Pan02 cells. We 
used lentiviral infection to generate Pan02 cell lines stably 
expressing control non-targeting shRNA or NMT1 shRNA 
along with GFP as a marker of infection (Figure 6A, 6C). 
Both cell lines were cultured for 6h in the presence or 
absence of tris DBA and processed for cilia detection. 
Importantly, silencing of NMT1 decreased cilia formation 
in Pan02 cells to a level that was comparable to the 
effect of tris DBA (Figure 6B and Figure 4A). This result 
indicated that the effect of tris DBA in cilia formation is 
mediated through NMT1. Furthermore, these data suggest 
that NMT1 is a novel regulator of cilia. 
Since NMT1 affects the myristoylation of SFK, we 
analyze whether SFKs were the target of NMT1 in cilia 
formation. We used the SFK inhibitor SU6656 and its 
derivative SU11333 to probe for an effect of SFK activity 
in cilia formation. We incubated Pan02 cells with these 
inhibitors or vehicle control and assay for cilia formation 
6 h after treatment (Figure 7). SFK inhibition was verified 
by analyzing the tyrosine phosphorylation levels of Stat3 
on the SFK-specific residue 705 (Figure 7B). Inhibition 
of SFKs in Pan02 cells did not affect cilia formation 
(Figure 7A), indicating that NMT1 regulated cilia through 
effects on a substrate other than SFKs. 
In summary, we show here that the NMT1 small 
molecule inhibitor tris DBA significantly decreased 
pancreatic primary tumor growth and metastasis of 
Pan02 cell in an orthotopic model in vivo. Tris DBA 
affected pancreatic cancer cell proliferation and colony 
formation in vitro, which could explain the reduction 
in primary tumor growth in vivo. Importantly, tris DBA 
decreased pancreatic cancer cell migration in response to a 
gradient of soluble factors (chemotaxis), at least in part by 
decreasing the ability of cancer cells to elaborate cilia in 
an NMT1-dependent and SFK-independent manner. The 
effect of tris DBA on cilia formation and chemotaxis could 
explain the effectiveness of this compound on diminishing 
metastasis in vivo. Finally, we described NMT1 as a novel 
regulator of cilia formation and tris DBA as a novel 
inhibitor of cilia formation.
DISCUSSION
Pancreatic carcinoma remains one of the most 
intractable solid tumors, with 5 year survival rates 
remaining around 20%. The most widely used therapeutic 
is gemcitabine, although other combinations such as 
gemicitabine/erlotinib and folfirinox may demonstrate 
increased survival. Even with these combinations, 
pancreatic carcinoma is usually highly lethal. Both 
intrinsic and extrinsic factors contribute to the poor 
response of pancreatic carcinoma to chemotherapy and 
radiation.
Intrinsic factors include the oncogene and tumor 
suppressor profile of pancreatic adenocarcinoma. The most 
common mutation in pancreatic carcinoma is that of Kras, 
and Kras is mutated in a number of other epithelial tumors, 
such as colon and non-small cell lung carcinoma. No 
specific inhibitor of Kras has been discovered, and Kras is 
often considered “undruggable”. Other common mutations 
in pancreatic carcinoma include mutation in p53, loss of 
expression of p16ink4a, and loss of the TGF beta signaling 
molecule SMAD4/dpc4 (deleted in pancreatic cancer 4) 
[1, 13–15]. Epidermal growth factor (EGF) is upregulated 
in approximately 60% of adenocarcinomas of the pancreas, 
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providing a rationale for the use of EGFR inhibitors in 
pancreatic carcinoma [16, 17].
Extrinsic factors include anatomic location and 
desmoplastic stroma. The stroma has been widely 
recognized to contribute to resistance of pancreatic 
carcinoma to chemotherapy. Attempts to alleviate 
desmoplasia to augment chemotherapy development have 
been mixed. Pancreatic epithelial cells secrete the ligand 
sonic hedgehog (Shh), which stimulates desmoplasia [5]. 
In a genetic mouse model of pancreatic carcinoma, 
treatment with a Shh inhibitor, IPI-926, led to decreased 
desmoplasia and increased efficacy of gemcitabine [18]. 
As of this date, combination vismodegib and gemcitabine 
have not yielded increased progression free or overall 
survival [4].
Here we demonstrated that tris DBA, an inhibitor 
of NMT1 is effective at reducing growth and metastasis 
of pancreatic cancer in vivo, indicating that NMT1 may 
be a novel therapeutic target in pancreatic cancer. Heme 
oxygen mediated carbon monoxide release and direct 
releasers of carbon monoxide have been shown to inhibit 
the growth of pancreatic carcinoma xenografts in vivo and 
block the phosphorylation of VEGFR2 [19]. Further study 
is required to determine whether the potent in vivo effects 
of Tris DBA palladium are mediated in part through 
carbon monoxide generation.
Tris DBA inhibited the growth of Pan02 primary 
tumors in vivo and had a striking effect in decreasing the 
formation of metastatic lesions. The effect in primary 
tumor growth was consistent with reduced proliferation 
and colony forming ability of pancreatic cancer cells 
treated with tris DBA in vitro. Interestingly, the inhibitory 
effect of tris DBA on the metastatic ability of Pan02 
cells is likely mediated through the inhibition of directed 
Figure 4: Cilia formation is disrupted by tris-DBA treatment in pancreatic cancer cells. Pan02 (A) or PANC1 (B) cells were 
cultured in the presence or absence of tris-DBA (1 mM) for 6 h and processed for detection of cilia by acetylated tubulin staining. Percent 
of cells forming cilia was quantified in at least 200 cells per condition in three independent experiments. The graphs show average ± S.D. 
for the percent of cells forming cilia in a representative experiment. (*) p < 0.0005 (Student’s t-test) in (A) and (*) p < 0.001 (Student’s 
t-test) in (B). (C) Representative images of cilia in Pan02 cells treated with tris DBA (1 µM) or vehicle control. (D) Representative images 
of cilia in PANC1 cells treated with tris-DBA (1 µM) or vehicle control. Arrowheads, cilia. Bars, 5 µm.
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Figure 5: Tris DBA treatment decreases cilia formation in Pan02 orthotopic tumors. (A) Percent of cells forming cilia in 
tumor sections from control and tris DBA-treated mice was quantified in 15 randomly chosen fields representing at least 500 cells per 
condition. The graph show average ± S.E.M. for the percent of cells forming cilia. (*) p < 0.005 (Student’s t-test). (B) Representative 
images of acetylated tubulin-stained tumor sections from the indicated groups. Circles indicate cilia and asterisk indicates a mitotic spindle 
(positive control for the staining). Bar, 2 µm.
Figure 6: NMT1 is necessary for cilia formation in Pan02 cells. (A) Pan02 lines expressing control non-targeting shRNA or 
NMT1 shRNA were cultured for 20 h and processed for detection of cilia by acetylated tubulin staining. (A) Percent of cells forming cilia 
was quantified in at least 250 cells per condition in three independent experiments. The graph shows average ± S.E.M. for the percent of 
cells forming cilia in a representative experiment out of three independent experiments. (*) p < 0.0001 (Student’s t-test). (B) Protein extracts 
from control non-targeting shRNA or NMT1 shRNA Pan02 cells were processed for electrophoresis and immunoblotting with NMT1 
and Actin antibodies. (C) Representative images of cilia (arrowheads) in Pan02 lines expressing control non-targeting shRNA or NMT1 
shRNA. GFP is a marker of shRNA expression. Bar, 10 µm.
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cell migration, which facilitates intravasation, the step 
preceding metastatic dissemination. Directed cancer 
cell migration towards a soluble extracellular factor 
(chemotaxis) is often modeled in vitro by using a gradient 
of FBS to mimic the growth factor or cytokine gradients 
to which cancer cells are exposed in vivo. Using this 
assay, we uncovered an inhibitory effect of tris DBA in 
directed migration (chemotaxis), which was in contrast 
with the lack of effect of this compound in non-directed 
migration (chemokinesis). Chemotaxis is comprised 
of chemosensing, polarization and locomotion [11]. 
Chemosensing and polarization are specific to chemotaxis, 
whereas chemokinesis and chemotaxis both result in 
locomotion. The specific effect of tris DBA in chemotaxis 
but not in chemokinesis suggested that locomotion was not 
directly impaired by this compound, in agreement with the 
lack of effect of tris DBA on the general appearance of the 
actin cytoskeleton or in the formation of focal adhesions 
detected with FAK staining. Cilia are microtubule-based 
structures that transduce extracellular signals to regulate 
multiple cellular functions including cell migration [12]. 
Cilia regulate directed migration of fibroblasts in response 
to PDGF-aa [20]. Furthermore, the formation of cilia is 
necessary for Hedhehog and Wnt signaling [21]; which are 
known regulators of cell migration. The formation of cilia 
by pancreatic cancer cells is impaired by oncogenic k-Ras 
in mice [22]. However, we detect robust cilia formation in 
Pan02 and PANC1 cells, suggesting that these pancreatic 
cancer cells are cilia-dependent. Recent studies indicate 
that impaired cilia formation is not a general phenomenon 
in pancreatic cancer, where the formation of cilia in a 
subset of lesions correlates with poor prognosis in clinical 
samples from pancreatic ductal adenocarcinoma patients 
[10]. Furthermore, recent evidence indicates that cilia 
disruption may not be a common feature in cancer, with 
some cancers actually relying in ciliary signaling [12].
Our data indicate that Pan02 pancreatic cancer 
cells depend on cilia formation for directional migration 
towards soluble factors in vitro. Importantly, we describe 
here that cilia are regulated by NMT1 and, therefore, a 
target for the NMT1 inhibitor tris DBA. This suggests a 
mechanism by which this compound decreases chemotaxis 
in vitro and diminishes metastasis in vivo. SFKs members 
including c-Src are associated with tumor progression and 
metastasis in a variety of cancers, including pancreatic 
cancer [7]. SFK member are known NMT1 targets 
Figure 7: SFK activity is not required for cilia formation in Pan02 cells. (A) Pan02 cells were treated tris-DBA (1 µM) or 
the SFK inhibitors Su6656 (5 µM) or Su11333 (1 µM) for 6 hours. Cells were stained with acetylated tubulin to detect cilia. Percent of 
cells forming cilia was quantified in at least 200 cells per condition in three independent experiments and represented as average ± S.E.M. 
(*) p < 0.001 (Student’s t-test). (B) Pan02 cells were treated with tris-DBA (1 µM) or the SFK inhibitors Su6656 (5 µM) or Su11333 
(1 µM) for 6 hours. Cell extracts were processed for immunoblotting with p(Y705) Stat3, total Stat3 and Tubulin antibodies to assess the 
effectiveness of SFK inhibition.
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[23], and their localization and function is regulated by 
N-terminal myristoylation. The SKF inhibitor SU6656 [24] 
and its derivative SU11333 [25] were used to probe for a 
role of SFKs downstream NMT1 in cilia formation. The 
lack of effect of SFK inhibitors in this context indicated 
that NMT1 was modulating cilia formation in Pan02 
cells in a SFK-independent manner. These results are in 
agreement with an inhibitory role of increased Src activity 
in ciliogenesis in mouse embryonic fibroblasts [26]. It is 
possible that tris DBA decreases N-myristoylation and 
ciliary membrane localization of additional proteins that 
are important for cilia formation. Indeed, myristoylation 
targets proteins to the eukaryotic ciliary membrane [27] 
and several ciliary proteins are myristoylated, including 
Cystin [28] and the ciliopathy protein nephrocystin-3 or 
NPHP3 [29]. In addition, many ciliary proteins identified 
by proteomic analysis are predicted to be N-myristoylated 
[30]. Further research will be necessary to determine the 
specific targets of tris DBA at cilia as well as the signaling 
mechanisms that regulate cilia-dependent directed 
migration in pancreatic cancer cells. Several studies 
suggest that NMT1 activity is important for the progression 
of different malignancies including breast cancer [31], oral 
squamous cell carcinoma [32], colon carcinoma [33] and 
gallblader cancer [34]. Our findings suggest that NMT1 is 
a novel therapeutic target in pancreatic cancer and warrants 
further investigation of tris DBA as a potential novel 
treatment for pancreatic carcinoma.
MATERIALS AND METHODS
Cell lines
The murine pancreatic cancer cell line Pan02 
(Panc02) was obtained from National Cancer Institute and 
confirmed to be pathogen-free before use. PANC1 human 
carcinoma cells were obtained from ATCC. Cells were 
cultured in DMEM (Invitrogen) with 10% fetal bovine 
serum and maintained at 37oC in a humidified incubator 
with 5% CO2 and 95% air. 
Compounds
Tris DBA palladium was obtained from Sigma-
Aldrich (Catalogue number 328774), and was dissolved 
in ethanol for in vitro studies. The SFK inhibitors SU6656 
and SU11333 (prepared in DMSO) were a generous gift 
from Dr. Sara Courtneidge (OHSU, Portland, OR).
Antibodies
The following primary antibodies were used: anti-
p(S473) Akt, anti-Akt (total), anti-p(T202/Y204) Erk1/2, 
anti Erk1/2 (total), anti-p(Thr389) p70 S6K, anti-FoxM1, 
anti-p(S705) Stat3, anti-Stat3 (total), anti-beta Tubulin 
(clone 13E5), all from Cell Signaling Technology. 
Anti-NMT1 was from Proteintech (11546-1-AP), anti-
acetylated tubulin antibody (clone 6-11B-1), from Sigma, 
anti-FAK antibody (clone 4.47) from EMD Millipore, and 
anti-b-actin from Santa Cruz.
Western blot
Protein lysates were obtained using RIPA buffer 
containing protease and phosphatase inhibitors. Protein 
concentration was quantified and lysates denatured 
with β-mercaptoethanol and heat at 95°C for 5 minutes. 
After SDS-PAGE, proteins were transferred to PVDF 
membranes. The blots were then incubated at room 
temperature for 1 hour in 5% non-fat dry milk in tris-
Buffered Saline and Tween 20 (TBST) and blotted 
overnight at 4°C with the corresponding primary 
antibodies. Afterwards they were washed 3× with TBST 
and incubated at room temperature for 1 hour with 
the corresponding secondary antibody. Detection was 
achieved using the Bio-Rad chemi-dock and imaging 
software, Image Lab 4.0 software or an infrared imaging 
system (Odyssey; LI-COR Biosciences).
Proliferation assay
5 × 104 Pan02 cells per well were plated in a 
24-well plate. Cells were washed with 1× PBS and treated 
in quadruplicates for 24 hours. The treatment was then 
removed and the cells were washed with PBS, trypsinized 
and counted. Cells were counted using a Beckman Z-1 
Coulter Counter.
Colony forming assay
500 cells per well were seeded in 6-well plates and 
treated with the indicated concentrations of tris DBA 
palladium in triplicates 24 h after plating. Plates were 
incubated for 6 days in the presence of compound and 
processed for crystal violet staining. Plates were scanned 
and the number of colonies manually counted.
Animal studies
All animals were housed in pathogen-free facility 
with access to food and water ad libitum. Experiments were 
approved and performed in accordance with the Institutional 
Animal Care and Use Committee at the University of 
Texas Southwestern Medical Center. C57BL/6 mice were 
purchased from on campus supplier. Six to eight week 
old male mice, in a group of five for vehicle control and 
a group of seven for tris DBA palladium, were injected 
orthotopically with 5 × 105 Pan02 cells and randomized 
1 week after tumor cell injection to receive 3 weekly 
i.p. injections of vehicle (coconut oil 100 µL), or tris 
DBA palladium (6.4 mg/kg). Mice were sacrificed when 
moribund after 4 weeks. At the time of sacrifice, orthotopic 
tumors were removed in bloc to determine primary tumor 
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burden. Gross metastatic events were identified through 
visual inspection of lymph node basins, liver, peritoneum, 
diaphragm and spleen. Samples were fixed in 10% formalin 
or snap frozen in liquid nitrogen for further studies. Data 
were analyzed using GraphPad software (GraphPad 
Software, San Diego, CA). Results are expressed as mean 
+/− SEM. Data were analyzed by one way ANOVA with 
differences considered significant at p < 0.05. 
Trans-well migration assay
We used 8 µm pore polycarbonate membranes 
(Corning). Cells were seeded in triplicate  (1 × 105 per 
insert) in the presence or absence of Tris-DBA (1 µM) in 
500 µl of medium containing 1% (for chemokinesis assay) 
or 10% FBS (for chemotaxis assay). The lower chamber 
was filled with 750 µl of medium containing 10% FBS. 
After 6 h at 37°C, inserts were washed in PBS and cells in 
the upper side of the membrane removed with wet cotton-
tipped swaps. Inserts were fixed in 4% paraformaldehyde 
for 15 minutes, followed by one PBS wash and incubation 
in a crystal violet solution (0.1% crystal violet in 
30% methanol) for 30 minutes. Inserts were washed 
extensively with distilled water and let dry. Migrated cells 
were quantified under a microscope (inverted CKX31 
Olympus) in at least six random fields per insert. Pictures 
were taken with an inverted IX81 Olympus Wide Field 
and Fluorescence Microscope (using an UPlan Apo 
10× objective) equipped with a color cooled CCD Spot 
RT3 camera (Diagnostic Instruments Inc.) and MetaMorph 
software (UIC dev. of Molecular Devices). Color digital 
images were inverted using Adobe Photoshop software 
(Adobe Inc).
Crystal violet assay
Cells were seeded in triplicate in 96-well tissue 
culture plates (2 × 104 per well), in the presence or absence 
of tris-DBA (1 µM) in 500 µl of medium containing 1% or 
10% FBS. After 6 h cells were stained with crystal violet 
solution (0.1% crystal violet in 30% methanol) for 30 
minutes, washed extensively with distilled water and let 
dry. Stain was eluted in 150 µl of 1% SDS in water for 
30 minutes. An aliquot of 100 µl per well was transferred 
to a clean 96-well plate and absorbance was measured 
at 570 nm using a microplate reader (EL×800; BioTek 
Instruments Inc.).
Detection and quantification of cilia in cells
Pan02 cells (4 × 104 per well) were seeded on 12-well 
plates containing 18 mm diameter glass coverslips in 
the presence or absence of tris DBA (1 µM) in medium 
containing 10% FBS and incubated at 37°C for 6 
or 20 h. Cells were washed with PBS and fix in 4% 
paraformaldehyde for 10 minutes. After 30 minutes of 
blocking with PBS containing 0.1% Triton X-100 and 
3% BSA, cells were incubated with a 1:1000 dilution of 
anti-acetylated tubulin antibody in PBS containing 0.1% 
Triton X-100 and 0.3% BSA for 2 hours at RT. Cells were 
washed with PBS containing 0.1% Triton X-100 and 
incubated with a 1:500 dilution of Alexa 488-conjugated 
goat anti-mouse antibody (Invitrogen) and 1:500 dilution 
of Alexa 568-conjugated phalloidin (Invitrogen) in 
PBS containing 0.1% Triton X-100 and 0.3% BSA for 
1 hour at RT. Cells were washed and mount in medium 
containing DAPI (Vector Labs.). Images were obtained 
in a fluorescent microscope (Axioplan 2; Carl Zeiss) 
equipped with a charge-coupled device camera (AxioCam 
HRm; Carl Zeiss) and AxioVision software (Carl Zeiss). 
Quantification was performed on 10 randomly acquired 
images (representing around 200 cells per coverslip) 
obtained at 20× magnification. 
Detection and quantification of cilia in tumor 
sections
Tumors were fixed in formalin, paraffin-embedded 
and sectioned. Sections were de-paraffined using Xylene 
and Ethanol and re-hydrated in distilled water and PBS. 
An acidic antigen retrieval solution was used before 
incubation of samples with the primary antibody (1:2,000) 
overnight at 4°C. After extensive washing, samples were 
incubated with Alexa 488-conjugated anti-mouse antibody 
(1:400) for 2 hours. Sections were mounted in Vectashield-
containg DAPI (Vector Labs). Images were obtained 
in a fluorescent microscope (Axioplan 2; Carl Zeiss) 
equipped with a charge-coupled device camera (AxioCam 
HRm; Carl Zeiss) and AxioVision software (Carl Zeiss). 
Quantification was performed on 15 randomly acquired 
images (representing around 90 cells per field) obtained at 
40× magnification. Number of nuclei per section was used 
for normalization.
Generation of NMT1 deficient Pan02 cell lines
Pan02 cells were infected with lentiviral particles 
generated from pLKO.1 puro CMV-turbo GFP constructs 
expressing either control non-targeting shRNA (SHC003, 
Sigma) or NMT1 shRNA (SHCLNV-NM_008707, 
TRCN0000055163, Sigma). Cells were selected with 
Puromycin (5 µg/ml) for 7 to 10 days. NMT1 knockdown 
was verified by immunoblotting using an anti-NMT1 
antibody.
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